Literature DB >> 7933174

Bladder cancer and the risk of smoking-related cancers during followup.

E Salminen1, E Pukkala, L Teppo.   

Abstract

The risk of smoking-related secondary cancers developing in bladder cancer patients was studied. The study population consisted of 10,014 bladder cancer patients reported to the Finnish Cancer Registry between 1953 and 1989. The risk of contracting a new primary cancer was estimated as a standardized incidence ratio, defined as the ratio of the observed and expected numbers of cases. Of 660 secondary cancers (6.6%) observed (standardized incidence ratio 0.96) 44% were considered to be smoking-related. Lung cancer was the most common secondary cancer (30% overall), and it occurred significantly more often than expected (standardized incidence ratio 1.31, 95% confidence interval 1.13 to 1.50). Also, larynx cancer among men (standardized incidence ratio 1.67, 95% confidence interval 0.95 to 2.79) and kidney cancer among women (standardized incidence ratio 3.55, 95% confidence interval 1.84 to 6.20) were found more often than expected. These excess risks were observed up to 20 years after diagnosis of bladder cancer. Therefore, bladder cancer patients experience an excess risk of smoking-related new tumors, which must be acknowledged during the initial evaluation and regular followup of such patients.

Entities:  

Mesh:

Year:  1994        PMID: 7933174     DOI: 10.1016/s0022-5347(17)32435-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  10 in total

1.  Practical implementation of an existing smoking detection pipeline and reduced support vector machine training corpus requirements.

Authors:  Richard Khor; Wai-Kuan Yip; Mathias Bressel; William Rose; Gillian Duchesne; Farshad Foroudi
Journal:  J Am Med Inform Assoc       Date:  2013-08-06       Impact factor: 4.497

2.  Urothelial cancer and the diagnosis of subsequent malignancies.

Authors:  Deepak K Pruthi; Zoann Nugent; Piotr Czaykowski; Alain A Demers
Journal:  Can Urol Assoc J       Date:  2013 Jan-Feb       Impact factor: 1.862

3.  Is there evidence for a multidisciplinary follow-up after urological cancer? An evaluation of subsequent cancers.

Authors:  M J Mathers; J Zumbe; S Wyler; S Roth; M Gerken; F Hofstädter; T Klotz
Journal:  World J Urol       Date:  2008-04-18       Impact factor: 4.226

4.  Patients with a Previous History of Malignancy Undergoing Lung Cancer Screening: Clinical Characteristics and Radiologic Findings.

Authors:  Darragh F Halpenny; Jane D Cunningham; Niamh M Long; Ramon E Sosa; Michelle S Ginsberg
Journal:  J Thorac Oncol       Date:  2016-05-17       Impact factor: 15.609

5.  Risk of second primary malignancies among cancer survivors in the United States, 1992 through 2008.

Authors:  Nicholas Donin; Christopher Filson; Alexandra Drakaki; Hung-Jui Tan; Alex Castillo; Lorna Kwan; Mark Litwin; Karim Chamie
Journal:  Cancer       Date:  2016-07-05       Impact factor: 6.860

6.  Lung cancer patients with previous or simultaneous urologic cancers.

Authors:  Kunihiko Miyazaki; Hiroaki Satoh; Katsunori Kagohashi; Koichi Kurishima; Hiroichi Ishikawa; Morio Ohtsuka; Kiyohisa Sekizawa
Journal:  Med Oncol       Date:  2008-04-05       Impact factor: 3.064

7.  [Interdisciplinary oncologic after-care exemplified by second primary tumors after bladder carcinoma].

Authors:  T Klotz; F Hofstädter; M Gerken
Journal:  Urologe A       Date:  2003-06-25       Impact factor: 0.639

8.  Lung cancer screening in patients with previous malignancy: Is this cohort at increased risk for malignancy?

Authors:  Elisabeth O'Dwyer; Darragh F Halpenny; Michelle S Ginsberg
Journal:  Eur Radiol       Date:  2020-07-29       Impact factor: 5.315

Review 9.  Controversies in the treatment of invasive urothelial carcinoma: a case report and review of the literature.

Authors:  Vicente Guillem; Miguel Angel Climent; Javier Cassinello; Emilio Esteban; Daniel Castellano; José Luis González-Larriba; Pablo Maroto; Carlos Camps
Journal:  BMC Urol       Date:  2015-03-13       Impact factor: 2.264

10.  Network-based analysis of diagnosis progression patterns using claims data.

Authors:  Eugene Jeong; Kyungmin Ko; Seungbin Oh; Hyun Wook Han
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.